Royal Bank Of Canada Sorrento Therapeutics, Inc. Transaction History

Royal Bank Of Canada

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.74 - $1.83 $44,900 - $111,038	60,677 Added 565.28%	71,411 $63,000
Q3 2022 Nov 14, 2022	BUY	$1.51 - $2.88 $1,143 - $2,180	757 Added 7.59%	10,734 $16,000
Q2 2022 Aug 15, 2022	SELL	$1.24 - $2.33 $35,034 - $65,831	-28,254 Reduced 73.9%	9,977 $20,000
Q1 2022 May 16, 2022	SELL	$2.0 - $4.9 $330,168 - $808,911	-165,084 Reduced 81.2%	38,231 $88,000
Q4 2021 Feb 14, 2022	BUY	$4.65 - $7.23 $707,757 - $1.1 Million	152,206 Added 297.81%	203,315 $946,000
Q3 2021 Nov 15, 2021	BUY	$7.41 - $10.99 $94,603 - $140,309	12,767 Added 33.3%	51,109 $390,000
Q2 2021 Aug 16, 2021	BUY	$6.35 - $10.0 $243,471 - $383,420	38,342 New	38,342 $372,000

5.47M

Ticker SRNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 449,952,000
Market Cap $148M
Description
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library an...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.